Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak executed an automatic sale of 10,348 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The transaction was carried out under a durable automatic sale instruction to cover tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. After this sell-to-cover transaction, Nayak directly held 332,412 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director and officer Pravin Dugel reported an open‑market sale of 124,882 common shares at a weighted average price of $9.04 per share. The transaction was made under a durable automatic sale instruction adopted on February 21, 2024 to satisfy tax withholding obligations from restricted stock units vesting on February 11, 2026.
After this sale, Dugel holds 3,033,078 common shares directly.
Ocular Therapeutix Chief Medical Officer Nadia Waheed reported an open-market sale of 7,863 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The sale was made under a durable automatic sale instruction to cover tax withholding on vested restricted stock units and was not a discretionary trade. After this transaction, she directly holds 318,417 shares.
Ocular Therapeutix Inc. is the subject of an updated ownership report from Venrock-affiliated investment entities. The Schedule 13G/A (Amendment No. 3) shows the group beneficially owning 6,862,972 shares of common stock, representing 3.2% of the company as of December 31, 2025.
This stake is held across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., with management entities and individuals Nimish Shah and Bong Y. Koh sharing voting and dispositive power. The filing notes the securities are not held for the purpose of changing or influencing control of Ocular Therapeutix.
Ocular Therapeutix shareholder Donald D Notman Jr. filed a notice of proposed sale under Rule 144 covering 11,446 shares of common stock. These shares came from restricted stock that vested under a registered plan on 02/11/2026 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The filing notes that 217,691,779 common shares were outstanding. Over the prior three months, the same seller disposed of 6,035 shares on 02/04/2026 for gross proceeds of 51,540.71 and 5,455 shares on 02/02/2026 for 49,872.88. The signer represents having no undisclosed material adverse information about Ocular Therapeutix.
Ocular Therapeutix insider Pravin Dugel filed to sell up to 124,882 shares of common stock. The shares were acquired on 02/11/2026 through restricted stock vesting under a registered plan and are expected to be sold around 02/12/2026 on the NASDAQ through Morgan Stanley Smith Barney LLC.
The filing notes that 217,691,779 shares of Ocular Therapeutix common stock are outstanding. It also discloses a prior sale by Dugel of 19,530 shares of common stock on 11/24/2025 for gross proceeds of 235,082.61.
Ocular Therapeutix insider Steve Meyers has filed a Form 144 to sell 6,864 shares of common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on or about February 12, 2026, with an indicated aggregate market value of $62,034.09.
The 6,864 shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. Over the past three months, Meyers has already sold 4,408 shares for $37,636.39 and 3,052 shares for $27,903.83. Shares outstanding were 217,691,779 at the time referenced.
Ocular Therapeutix shareholder files notice to sell shares under SEC Rule 144. The filing covers up to 10,348 shares of common stock, with an aggregate market value of $93,560.41, to be sold through Morgan Stanley Smith Barney on NASDAQ.
The shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. The notice also reports a prior sale over the last three months of 1,878 common shares for gross proceeds of $22,616.19.
A shareholder of OCUL has filed a notice of proposed sale under Rule 144 for 7,863 shares of common stock. The shares have an aggregate market value of $71,082.31 and are intended to be sold on NASDAQ around 02/12/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
The securities were acquired on 02/11/2026 as restricted stock vesting under a registered plan from the issuer, in the same amount of 7,863 shares, with no separate cash payment listed.
Deep Track Capital and affiliates report a significant ownership stake in Ocular Therapeutix, Inc. They beneficially own 11,234,132 shares of common stock, representing 5.13% of the company as of February 10, 2026.
The position is held through Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and individual reporting person David Kroin, who share dispositive power over the same 11,234,132 shares. This amount includes 1,163,718 pre-funded warrants that are exercisable into common stock, subject to a 9.99% “Maximum Percentage” limitation on beneficial ownership after exercise.
The ownership percentage is calculated using 218,855,497 shares, combining 217,691,779 shares outstanding as of February 2, 2026 and the shares underlying the pre-funded warrants. The filers certify that the securities are not held for the purpose of changing or influencing control of Ocular Therapeutix.